药物释放膀胱内漂浮技术用于非肌层浸润性膀胱癌序贯吉西他滨和多西他赛治疗
本研究开发了一种药物释放膀胱内漂浮技术(DRIFT)装置,用于控制序贯递送吉西他滨和多西他赛(Gem/Doce)以优化非肌层浸润性膀胱癌(NMIBC)治疗,同时允许患者活动和自行取出。装置在体外、羊和兔模型中评估,结果显示通过涂层优化可调节药物释放,多西他赛组织穿透随吉西他滨浓度和停留时间增加而增强。
要点
- DRIFT装置可实现吉西他滨和多西他赛的序贯控制释放,多西他赛在吉西他滨预处理期间可靠保留长达120分钟。
- 吉西他滨浓度升高和停留时间延长(达4小时)可显著增强多西他赛的深部组织穿透。
- 该平台未来需体内验证安全性和治疗潜力,并可能扩展至尿路感染和间质性膀胱炎。
核心结论
- DRIFT装置能够控制序贯递送吉西他滨和多西他赛,在吉西他滨预处理期间可靠维持多西他赛封闭长达120分钟。
研究设计与样本
- 研究开发了由三维打印多孔管、乳胶套、可溶解端盖和患者移除缝线组成的DRIFT装置,并在体外、美利奴羊和兔膀胱组织中评估性能。
主要发现
- 通过FluoroPel涂层优化,溶解时间从零涂层到三涂层显著延长(P < 0.001)。
- 多西他赛释放动力学在2.0至3.0 mL体积之间趋于平稳。
- 羊研究显示与体外测试相似的时间控制药物释放。
- 吉西他滨浓度递增增强多西他赛组织穿透,峰值浓度达0.45 mg/mL vs 对照组0.08 mg/mL。
- 延长吉西他滨停留时间(达4小时)进一步改善多西他赛递送,显著增强深部组织穿透(P < 0.001)。
临床怎么用
- 该装置可能简化NMIBC的序贯膀胱内Gem/Doce治疗,允许患者活动并自行移除装置。
局限性
- 未来需体内验证以确立安全性和治疗潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To develop a drug-releasing intravesical floating technology (DRIFT) device for controlled sequential delivery of gemcitabine and docetaxel (Gem/Doce) to optimise the treatment of non-muscle-invasive bladder cancer (NMIBC) while enabling patient mobility and self-removal, as sequential intravesical Gem/Doce has been increasingly utilised but has logistical limitations requiring prolonged clinic visits and patient immobilisation. MATERIALS AND METHODS: The DRIFT device features a three-dimensional printed perforated tube with latex sleeve, dissolvable polyvinyl acetate and polyvinylpyrrolidone end cap with adjustable fluorinated polymer (FluoroPel) coating, and patient-removal suture. A 14-F catheter is placed and intravesical gemcitabine is instilled. The deflated DRIFT device is inserted via catheter and inflated with docetaxel and air. The catheter is removed, allowing gemcitabine to dwell temporarily and be voided by the patient. The DRIFT device remains in the bladder and subsequently releases docetaxel in a controlled, delayed fashion, followed by patient removal. Its flexible, buoyant design supports patient mobility and maintains unimpeded urinary flow. Dissolution kinetics were evaluated using methylene blue, device performance was assessed in Merino sheep, and docetaxel tissue penetration was evaluated in rabbit bladder tissue using high-performance liquid chromatography analysis. RESULTS: The DRIFT device demonstrated adaptable drug release through FluoroPel coating optimisation, with dissolution times extending significantly from zero to three coatings (P < 0.001). Docetaxel release kinetics plateaued between 2.0 and 3.0 mL volumes. Sheep studies revealed similar timed drug release as in vitro testing. Escalating gemcitabine concentrations enhanced docetaxel tissue penetration, with peak concentrations reaching 0.45 vs 0.08 mg/mL in controls. Extended gemcitabine dwell time (up to 4 h) further improved docetaxel delivery, achieving significant enhancement in deep tissue penetration (P < 0.001). CONCLUSION: The DRIFT enables controlled sequential delivery of Gem/Doce, reliably maintaining docetaxel containment for up to 120 min during gemcitabine pre-treatment. Future in vivo validation will establish safety and therapeutic potential. This platform has broader applications beyond NMIBC, including urinary tract infections and interstitial cystitis.
引用
- Rhodes AC, McClintic KA, Witt E, et al. Drug-releasing intravesical floating technology for sequential gemcitabine and docetaxel in non-muscle-invasive bladder cancer. BJU Int. 2025. PMID: 41178321. doi:10.1111/bju.70060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。